Dextran

Summary

Dextran (CHEMBL1697742) is a phase-3 clinical-stage oligosaccharide; indicated across 5 conditions including brain injury and hiv infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 5 conditions
• Clinical trials: 16
• Chemistry: 504.4 Da · C18H32O16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697742
Name	Dextran
Type	Oligosaccharide
Max phase	3
FDA approved	no
PubChem CID	5460037
Molecular formula	C18H32O16
Molecular weight	504.4
InChIKey	FZWBNHMXJMCXLU-BLAUPYHCSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)OC[C@H]([C@H]([C@@H]([C@H](C=O)O)O)O)O)O)O)O)O)O)O)O

IUPAC name: (2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal

Also known as: Dextran, Dextran 40, LMWD, DEXTRAN

Patent coverage: 1,235 distinct patent families (3,722 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
brain injury	3	MONDO:0043510	MONDO:0043510
HIV infectious disease	1	MONDO:0005109	EFO:0000764
refractive error	1	MONDO:0004892	HP:0000483
hyperopia	1	MONDO:0004891	HP:0000540
keratoconus	1	MONDO:0015486	MONDO:0015486

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
Not specified	7
PHASE4	4
PHASE1	2
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01282138	PHASE4	COMPLETED	Assessment of Alcon’s Ocular Image Quantification System
NCT01470118	PHASE4	COMPLETED	A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
NCT01732757	PHASE4	COMPLETED	A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT01978015	PHASE4	COMPLETED	Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG
NCT01152541	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT03070353	PHASE2/PHASE3	COMPLETED	Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
NCT02863809	PHASE1/PHASE2	COMPLETED	Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
NCT00000690	PHASE1	COMPLETED	Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers
NCT00001009	PHASE1	COMPLETED	A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)
NCT05008276	Not specified	RECRUITING	Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
NCT05530356	Not specified	ENROLLING_BY_INVITATION	Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
NCT06835023	Not specified	RECRUITING	Dextran 40 Plus Ringer’s Lactate Vs. Ringer’s Lactate Alone for Fluid Resuscitation in Acute Pancreatitis
NCT00000684	Not specified	COMPLETED	Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
NCT01743872	Not specified	COMPLETED	Optical Imaging Measurement of Intravascular Solution Efficacy Trial
NCT02286596	Not specified	COMPLETED	Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia
NCT05181969	Not specified	UNKNOWN	Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).